Zealand Pharma Launches ZUPREME-1 Study To Test Petrelintide In Obesity Treatment

Zealand Pharma A/S, a biotechnology company specialising in innovative peptide-based therapies, has announced the enrollment of the first participant in its ZUPREME-1 trial. This global Phase 2b study is evaluating the effects of petrelintide, a long-acting amylin analogue administered once weekly via subcutaneous injection, in individuals with obesity or overweight and weight-related co-morbidities. The trial aims to assess the treatment’s impact on body weight and its safety and tolerability compared to a placebo.

David Kendall, MD, Chief Medical Officer at Zealand Pharma, said in a statement, “The initiation of this large and comprehensive Phase 2b trial of petrelintide in people with overweight or obesity marks an important milestone for Zealand. Backed by strong and compelling clinical data reported to date, we are highly encouraged by the potential of petrelintide to represent a best-in-class alternative to incretin-based therapies and a future foundational therapy for weight management. We are expanding the development program for petrelintide and look forward to initiating the Phase 2b trial of petrelintide in people with overweight or obesity with type 2 diabetes in the first half of 2025.